Zacks Small Cap Forecasts Increased Earnings for Cingulate

Cingulate Inc. (NASDAQ:CING) – Equities research analysts at Zacks Small Cap increased their FY2024 earnings estimates for shares of Cingulate in a report released on Tuesday, November 12th. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will post earnings of ($9.50) per share for the year, up from their prior estimate of ($16.00). The consensus estimate for Cingulate’s current full-year earnings is ($12.51) per share. Zacks Small Cap also issued estimates for Cingulate’s Q4 2024 earnings at ($1.49) EPS, FY2025 earnings at ($2.33) EPS and FY2026 earnings at ($0.27) EPS.

Cingulate (NASDAQ:CING) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($1.83) EPS for the quarter, topping the consensus estimate of ($2.22) by $0.39.

Cingulate Stock Up 3.8 %

Shares of NASDAQ:CING opened at $4.33 on Thursday. The firm’s 50 day simple moving average is $4.78 and its 200-day simple moving average is $3.03. Cingulate has a one year low of $1.80 and a one year high of $152.40.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cingulate stock. Armistice Capital LLC bought a new position in shares of Cingulate Inc. (NASDAQ:CING) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 490,000 shares of the company’s stock, valued at approximately $157,000. Armistice Capital LLC owned about 6.67% of Cingulate as of its most recent SEC filing. Institutional investors and hedge funds own 41.31% of the company’s stock.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.